We then applied the SC-2 gene signature to five melanoma immunotherapy datasets, including 263 samples with anti-PD1 or anti-CTLA4 therapies, and found that a higher gene signature score was not only significantly associated with better responses (Figure 5G), but was also significantly associated with better survival under immunotherapy (Figure 5H). This evidence concerns the gene CTLA4 and melanoma.